We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
CytRx may be able to resume a Phase IIb clinical trial of its experimental drug arimoclomol for amyotrophic lateral sclerosis (ALS) after submitting data from a new animal study at the FDA’s request.